Cancer Research Annual Meeting 2010  Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cavallo, F.
Right arrow Articles by Calogero, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cavallo, F.
Right arrow Articles by Calogero, R. A.
[Cancer Research 61, 3518-3523, April 15, 2001]
© 2001 American Association for Cancer Research


Virology

Interleukin 12-activated Lymphocytes Influence Tumor Genetic Programs1

Federica Cavallo, Elena Quaglino, Loredana Cifaldi, Emma Di Carlo, Alessandra André, Paola Bernabei, Piero Musiani, Guido Forni2,, 3 and Raffaele A. Calogero3

Department of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, Italy [F. C., E. Q., L. C., P. B., G. F., R. A. C.]; Department of Oncology and Neuroscience, University of Chieti, 66100 Chieti, Italy [E. D. C., P. M.]; and Department of Genetics, General and Molecular Biology, University of Naples, 80134 Naples, Italy [A. A.]

T-lymphocytes (LYs) from normal and IFN-{gamma} knockout mice were activated by anti-CD3 and anti-CD28 antibodies and cultured in inserts in the presence of interleukin (IL)-12 (IL-12-activated LYs) or not (activated LYs). Their ability to modulate the genetic programs of two tumor lines growing at the bottom of transwells was evaluated. cDNA gene expression array, reverse transcription-PCR, and protein expression showed that LPS, transcription termination factor 1, transforming growth factor, and fibroblast growth factor genes were up-modulated by factors other than IFN-{gamma} released by activated LYs. The high levels of IFN-{gamma} released by normal IL-12-activated LYs up-modulated the expression of STAT1, IRF-1, LMP2, LMP7, monokine induced by IFN-{gamma}, monocyte chemoattractant protein 1, and angiopoietin 2 genes but down-modulated the expression of vascular endothelial growth factor. PA28, IFN-inducible protein 10, inducible NO synthetase, and macrophage-inhibitory protein 2 genes were up-modulated by factors released only by IL-12-activated LYs apart from IFN-{gamma}. The opposite modulations of vascular endothelial growth factor expression and of angiopoietin 2, monokine induced by IFN-{gamma}, IFN-inducible protein 10, and inducible NO synthetase by IL-12-activated LYs fit in well with the inhibition of angiogenesis that characterizes the antitumor activity of IL-12. T-LYs thus modify a tumor’s behavior so that it becomes a party to its own inhibition.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
M. Del Vecchio, E. Bajetta, S. Canova, M. T. Lotze, A. Wesa, G. Parmiani, and A. Anichini
Interleukin-12: Biological Properties and Clinical Application
Clin. Cancer Res., August 15, 2007; 13(16): 4677 - 4685.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. Pannellini, M. Spadaro, E. Di Carlo, E. Ambrosino, M. Iezzi, A. Amici, P. L. Lollini, G. Forni, F. Cavallo, and P. Musiani
Timely DNA Vaccine Combined with Systemic IL-12 Prevents Parotid Carcinomas before a Dominant-Negative p53 Makes Their Growth Independent of HER-2/neu Expression.
J. Immunol., June 15, 2006; 176(12): 7695 - 7703.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. Terra, I. Louis, R. Le Blanc, S. Ouellet, J. C. Zuniga-Pflucker, and C. Perreault
T-cell generation by lymph node resident progenitor cells
Blood, July 1, 2005; 106(1): 193 - 200.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. Quaglino, M. Iezzi, C. Mastini, A. Amici, F. Pericle, E. Di Carlo, S. M. Pupa, C. De Giovanni, M. Spadaro, C. Curcio, et al.
Electroporated DNA Vaccine Clears Away Multifocal Mammary Carcinomas in Her-2/neu Transgenic Mice
Cancer Res., April 15, 2004; 64(8): 2858 - 2864.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
P. Nanni, G. Nicoletti, C. De Giovanni, L. Landuzzi, E. Di Carlo, F. Cavallo, S. M. Pupa, I. Rossi, M. P. Colombo, C. Ricci, et al.
Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice
J. Exp. Med., October 29, 2001; 194(9): 1195 - 1206.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.